Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/48

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20210318334Materials and Methods for Improved Prediction of IGG Therapeutic Protein Exposure
US 14.10.2021
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Appl.No 17229124 Applicant Janssen Biotech, Inc. Inventor Yang Chen

Methods for predicting pharmacokinetics of an Immunoglobulin G (IgG) therapeutic protein based on a patient's level of rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA), or RF and ACPA. Methods disclosed herein also relate to methods for determining the therapeutically effective dose of an IgG therapeutic protein based on the levels of RF, ACPA, or RF and ACPA.

2.WO/2021/203828USE OF INHIBITOR IN PREPARATION OF DRUGS FOR TREATING SARS-COV-2 PNEUMONIA AND COMPLICATIONS THEREOF
WO 14.10.2021
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
Appl.No PCT/CN2021/075757 Applicant ACADEMY OF MILITARY MEDICAL SCIENCES, PLA Inventor WEI, Congwen
Provided is the use of an inhibitor in the preparation of drugs for treating SARS-CoV-2 pneumonia and complications thereof, wherein the inhibitor has one or more of the following properties: (1) reducing the binding of high-density lipoprotein to a receptor thereof; and (2) reducing the binding of the S protein of SARS-CoV-2 virus to cholesterol.
3.WO/2021/204743LARGE MOLECULE UNSPECIFIC CLEARANCE ASSAY
WO 14.10.2021
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Appl.No PCT/EP2021/058839 Applicant F. HOFFMANN-LA ROCHE AG Inventor BOLENDER, Anna-Lena
Herein is reported a method for determining non-specific clearance of an antibody comprising the steps of incubating the antibody, which is conjugated to a pH- sensitive fluorescent dye, with primary human endothelial cells, and determining the fluorescence intensity of the primary human endothelial cells, whereby an increase of the fluorescence intensity of the primary human endothelial cells above background level is indicative for non-specific clearance of the antibody.
4.WO/2021/205058METHOD FOR DETERMINING CORONAVIRUS AND KIT FOR THE SAME
WO 14.10.2021
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/FI2021/050026 Applicant MEDICORTEX FINLAND OY Inventor HAREL, Adrian
The present invention relates to a method for detecting coronaviruses from samples wherein the detecting is performed in the aid of sialic acid and/or O-glycan binding lectins. According to one embodiment the method comprises subjecting the coronavirus (200) to a solution (201) comprising a component (202) adapted to neutralize the coronavirus and a component (203) adapted to expose glycoproteins of the coronavirus. When the sample comprises the virus, the exposed glycoproteins bind to a lectin (206) of a conjugate (204) to form a complex (208). Exposure of an immobilized lectin (209) to the complex gives rise to another complex (210) on detection zone (205b) of the probe. Signal derived from the signal generating means (207) in the detection zone is an indication of the presence of coronavirus. The method relates also to kits for use in the method.
5.WO/2021/205433LATERAL FLOW TEST UTENSILS
WO 14.10.2021
Int.Class G01N 33/558
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
558using diffusion or migration of antigen or antibody
Appl.No PCT/IL2021/050374 Applicant RAPID BIO PASS LTD. Inventor TZIDON, Dekel
Lateral flow test utensils, testing kits and diagnostic methods are provided. The test utensils comprise, on one or more interconnected pad(s) made of capillary material and consecutively along a flow path of a sample: a sample-receiving region, optionally an antibodies-separation region configured to separate different types of immune components in the sample, a marking region comprising marked pathogen parts, a fixation region comprising fixated pathogen parts, and a control region. Marked pathogen parts (pathogen part(s) attached to indicator particles) are bonded by antibodies and/or T-cells in the sample, flow along pad(s) of the utensil and are then immobilized by fixated pathogen parts (rather than binding to anti-human antibodies as in the prior art) - to enhance the analytical sensitivity of the test. Disclosed lateral flow tests enable wide range, possibly home -use sensitive serological testing, allowing population-wide epidemiological monitoring.
6.WO/2021/207173UNIT DEVICE, METHOD, AND ASSEMBLY
WO 14.10.2021
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No PCT/US2021/025936 Applicant CHARM SCIENCES, INC. Inventor SALTER, Robert S.
Sample collection and analysis devices, methods, and assemblies are shown and described. In one embodiment, an assembly includes a sample collection device and a removable vial having a penetrable barrier seal to prevent access to the vial until at least one penetrable activation. The result is improved efficient and effective sample collection and analysis.
7.WO/2021/207683IMPROVED METHODS FOR EVALUATING LIVER FUNCTION
WO 14.10.2021
Int.Class G01N 30/72
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
30Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
02Column chromatography
62Detectors specially adapted therefor
72Mass spectrometers
Appl.No PCT/US2021/026695 Applicant HEPQUANT, LLC Inventor EVERSON, Gregory, Thomas
Improved methods and kits are provided for non-invasively evaluating liver function of a patient including rapidly and efficiently processing, detecting, and quantifying distinguishable compounds from patient blood or serum samples. A method is provided for estimating risk of experiencing a clinical event in 1 year for an individual patient having a chronic liver disease. Methods for determining hepatic reserve in a subject are provided.
8.WO/2021/207743ENRICHMENT OF ANTIGEN-SPECIFIC ANTIBODIES FOR ANALYTIC AND THERAPEUTIC USE
WO 14.10.2021
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Appl.No PCT/US2021/026927 Applicant VERAVAS, INC. Inventor CAINE SOLDO, Joshua
The present invention is directed to methods for using particles (e.g, microparticulate, nanoparticulate; magnetic, non-magnetic) comprising surfaces comprising capture moieties as described herein, to remove an interference as described herein, or enrich biomarkers, especially antibodies, prior to a diagnostic test, or to be isolated and used for prophylactic or therapeutic purposes.
9.20210315938Methods and Compositions for Retinal Neuron Generation in Carrier-Free 3D Sphere Suspension Culture
US 14.10.2021
Int.Class A61K 35/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
Appl.No 17273747 Applicant HEBECELL CORPORATION Inventor Feng Qiang

Provided herein, in one aspect, is a population of retinal neurons including photoreceptors precursor cells (PRPCs) generated in vitro from human pluripotent stem cells (hPSCs) that can be used as a cell source for regenerative therapies, drug discovery and disease modeling. Methods and compositions for making and using the same are also provided.

10.20210318264BIOSENSOR USING FET ELEMENT AND EXTENDED GATE, AND OPERATING METHOD THEREOF
US 14.10.2021
Int.Class G01N 27/414
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
27Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
26by investigating electrochemical variables; by using electrolysis or electrophoresis
403Cells and electrode assemblies
414Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
Appl.No 17139576 Applicant KOREA ELECTRONICS TECHNOLOGY INSTITUTE Inventor Kook Nyung LEE

A bio sensor using a FET element and an extended gate, and an operating method thereof are disclosed. A biosensor using a field effect transistor (FET) device and an extended gate electrode according to the present invention is characterized by comprising: an extended gate electrode connected to the FET element; a sensing electrode made of the same material as the extended gate electrode and on which a receptor antibody selectively recognizing a target molecule is fixed; and a reference electrode that maintains a constant potential and is selectively connected to the sensing electrode.